Loading
Uromigos-Bladder Cancer

The Uromigos

The Uromigos | August 22, 2022

John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.

The Uromigos Episode 187: Legends Series—Cora Sternberg
The Uromigos

| August 15, 2022

Cora Sternberg, MD, discusses her career that has spanned multiple continents.

The Uromigos

The Uromigos | May 9, 2022

Syed Hussein and Sam Funt describe their studies on this topic.

The Uromigos

The Uromigos | March 14, 2022

Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.

The Uromigos

The Uromigos | March 7, 2022

Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.

The Uromigos

The Uromigos | February 18, 2022

Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.

The Uromigos

The Uromigos | January 31, 2022

Dr. Joaquim Bellmunt gives an overview of the updated ESMO guidelines on bladder cancer.

The Uromigos

The Uromigos | December 13, 2021

Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022.

The Uromigos

The Uromigos | December 2, 2021

Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition.

The Uromigos

The Uromigos | September 17, 2021

Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.

The Uromigos

The Uromigos | September 17, 2021

Dr. Jonathan Rosenberg gives an overview of the NORSE Study.

The Uromigos

The Uromigos | August 23, 2021

Dr. Dean Bajorin discusses developments in bladder and collaboration in testis cancer.

The Uromigos

The Uromigos | July 23, 2021

Dr. Ashish Kamat walks through ongoing issues around surgery in urothelial cancer at EAU 2021.

The Uromigos

The Uromigos | June 7, 2021

Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.

The Uromigos

The Uromigos | June 7, 2021

Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.

The Uromigos

The Uromigos | June 7, 2021

The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.

The Uromigos

The Uromigos | June 7, 2021

Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.

The Uromigos

The Uromigos | May 19, 2021

Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.

The Uromigos

The Uromigos | May 4, 2021

Dr. Petros Grivas discusses the accelerated approval of sacituzumab govitecan in bladder cancer.

The Uromigos

The Uromigos | April 28, 2021

Dr. Andrea Apollo discusses highlights from the ODAC meeting regarding accelerated approvals for bladder cancer.